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Within the past decade seven randomized controlled trials
have been published comparing percutaneous transluminal
coronary angioplasty (PTCA) to coronary artery bypass
graft surgery (CABG) (1–7). The mortality rates and
important clinical outcomes during follow-up periods rang-
ing from one to five years varied slightly, but essentially each
study has shown that the mortality rates between the two
revascularization techniques are not significantly different.
However, patients randomly assigned to CABG universally
have a lower incidence of angina and less need for repeat
procedures during follow-up.
With one exception (3) all the trials required the study
population to include symptomatic patients with multivessel
disease (MVD) and who were suitable candidates for both
CABG and PTCA. Specifically excluded were patients with
extensive coronary disease unsuitable for PTCA and those
with poor left ventricular function. Most of the studies also
excluded, per protocol, patients who had prior CABG or
PTCA and those with very recent acute myocardial infarc-
tion (AMI). As a consequence, the resulting “MVD popu-
lation” included in these trials was decidedly lower risk than
the conventional MVD population for whom CABG is
usually recommended.
See page 51
The importance of this consideration has been demon-
strated in two observational studies that have utilized large
databases to compare PTCA and CABG (8,9). The New
York State database included information on more than
60,000 patients from 33 institutions followed for three years
undergoing either PTCA or CABG in New York (8). The
Duke database included approximately 6,000 patients un-
dergoing either procedure at that single institution (9). Both
databases include the detailed clinical and angiographic data
required to make proper risk adjustments on all patients.
This is considered essential in forming valid comparisons
among nonrandomized populations. The detailed angio-
graphic data permitted the investigators to categorize pa-
tients beyond the conventional, but simplistic, one-, two-,
and three-vessel disease classification and further stratify
patients according to whether the lesions were proximal or
distal in each of the major epicardial arteries. Both of these
reports clearly demonstrate that survivorship is superior in
patients undergoing CABG compared to PTCA in six of
the nine subsets of patients stratified according to lesions in
the proximal segments of the coronary arterial tree or
involvement of the left anterior descending artery. These
findings are consistent with those of Ringqvist et al. (10) in
seminal studies on the natural history of coronary artery
disease patients performed during the Coronary Artery
Surgery Study (CASS).
Based on these considerations the cardiology community
currently functions with an evidence-based mind-set that,
for patients with severe extensive coronary artery disease,
CABG is the preferred method of revascularization. How-
ever, for patients with less extensive multivessel disease who
could be treated successfully by either CABG or PTCA
there are practical reasons to consider PTCA as the more
“patient-friendly approach.” This is particularly true if both
the physician and patient accept the strategy of including
repeat PTCA as part of the “price to be paid” for selecting
the less invasive technique.
In this issue of the Journal, Rodriguez et al. (11) present
the first data from a randomized comparison of present-day
PTCR (coronary angioplasty with stenting) versus CABG,
indicating an improved outcome with PTCR. The primary
end point of this study from South America is the 30-day
incidence of major adverse cardiac events (MACE: death,
Q-wave myocardial infarction, stroke, and repeat revascu-
larization procedures). The incidence for PTCR was 3.6%
and for CABG 12.3% (p 5 0.002). Driving this combined
end point was the 30-day surgical mortality of 5.7% and a
Q-wave MI rate of the same magnitude (5.7%) when
compared to a PTCR mortality rate of 0.9% and a Q-wave
MI rate of 0.9% (p 5 0.013%). At one-year follow-up,
survival was 96.9% in the PTCR group and 92.5% in the
CABG group (p 5 0.017). As the Kaplan-Meier survival
curves demonstrate, the excess deaths among the surgically
assigned patients were confined to the first 30 days of
follow-up and after that the numbers of patients dying were
the same in each group. The same is true of the MI curves.
The study further reports that the need for repeat revascu-
larization procedures, while higher in the PTCR group
(16.8% vs. 4.8%, p 5 0.002), is substantially lower than the
need reported in earlier studies with conventional balloon
angioplasty (30% to 40%).
For many reasons, this report is certain to polarize any
readership interested in coronary revascularization into
those who applaud the work and those who condemn it.
The opponents are certain to criticize 30-day MACE as a
meaningless primary end point. It is widely recognized that
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Section of Cardiology, Boston University Medical Center, Boston,
Massachusetts.
Journal of the American College of Cardiology Vol. 37, No. 1, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01051-2
undertaking an intervention as major as CABG carries an
inherent procedural risk of mortality, Q-wave infarction,
and stroke that outweighs the comparable risks of the less
invasive procedure of conventional PTCA. Considering
existing data, the deployment of stents at the time of PTCA
not only decreases the incidence of restenosis but lessens the
occurrence of abrupt vessel closure and early reocclusion that
should further widen the gap of early morbidity and
mortality (12). These physicians will claim the primary end
point was selected in a preordained fashion to gain statistical
significance of PTCR over CABG but fails to address the
basic question of which strategy is better in the longer run.
Proponents of the study will agree with the investigators’
opening sentence: “previous randomized studies comparing
balloon angioplasty vs. CABG have demonstrated equiva-
lent safety results.” Even though none of the previous
randomized comparisons was powered to examine early
mortality or complication rates, the largest of these trials,
BARI, showed a significantly higher incidence of in-
hospital Q-wave infarction, respiratory failure, reoperation
for bleeding and wound dehiscence/infection in the CABG
arm compared to PTCA (7). Among the latter group,
however, both emergency and nonemergency CABG as well
as emergency and nonemergency PTCA were significantly
higher. In contrast, no statistically significant differences
existed in either the cumulative survival curves or survival
free of Q-wave myocardial infarction between the two
groups over five years of follow-up (7).
Thus, members of the ERACI II study group could
justify their contention that, if there is no long-term
difference in these two outcomes in patients with symptom-
atic multivessel disease who were judged eligible for either
procedure, it is important to examine which is the safer
procedure. Accordingly, they properly sized their study
population on “the assumption that either death, MI, repeat
procedures and stroke would occur during hospitalization in
10% to 12% of patients assigned to CABG and in keeping
with recent PTCR experience, in 3% to 4% of patients
assigned to PTCA.” This provided a power of 0.9 and an
alpha error of 0.05. Although they give no details on how or
who will accomplish it, the investigators planned a one-,
three-, and five-year follow-up to study the secondary end
points of anginal status, completeness of revascularization,
and costs. Curiously, not stated (but eventually reported)
was the need for repeat revascularization procedures in this
industry-sponsored stent study.
The seemingly excessively high operative mortality (OM)
rate of 5.7% in the ERACI II study (11) will also be the
focus of much criticism. This, however, seems misplaced
because with a small sample size of 450 patients and only 15
total deaths, the confidence intervals of the point estimate
are extremely wide and renders the 5.7% figure quite
imprecise. It is similar, however, to the 4.7% mortality rate
reported in the earlier randomized comparison presented by
these investigators in their very underpowered ERACI I
study (2). It also falls within the range of other studies
selected mostly from South America but also includes the
VANQWISH trial from North America (13,14). The OM
rate is nearly fivefold what it was in BARI, EAST, and
CABRI, but the investigators maintain the 91% unstable
angina rate and the 22% incidence of peripheral vascular
disease rendered their population an unusually high-risk
group for undergoing CABG. Unfortunately, the annual
overall mortality rates for CABG at the individual partici-
pating sites in the ERACI II study (11) are not given and
the reader remains unable to judge the validity of this claim.
To their credit, the researchers did explore the operative
mortality of the surgically randomized patients stratified
according to chronic stable angina, unstable angina class II,
and unstable angina class III1C. Although the sample sizes
of each group were too small for robust statistical analysis,
an internal consistency showed a trend toward a greater
in-hospital mortality as the severity of unstable angina
worsened. We also know that, of the 1,076 patients who
qualified for randomization in this trial, 27% underwent
CABG outside the randomized study and their 30-day
mortality rate was 5.1% with a 5.2% Q-wave AMI rate. It
would be equally enlightening to know the operative mor-
tality of the 287 patients in the registry who did not qualify
for randomization but did undergo CABG. Left main
disease was present in 27%, an equal percentage had poor
left ventricular function, and 28% had multivessel disease
too extensive to be managed by PTCA. One would antic-
ipate an even higher OM rate in such a group.
It has been suggested that the large observational data-
bases that contain relevant revascularization data be used to
supplement information available from smaller-sized ran-
domized trials (8). During the 1996 to 1998 time frame of
ERACI II, more than 58,000 patients underwent CABG,
and approximately 88,000 underwent PTCA in New York
State, with all data entered into their respective Cardiac
Surgery and Angioplasty Registry files. Unstable angina was
present in 27,589 patients undergoing CABG and their
OM rate was 3.3%, which is two and a half times greater
than the OM rate for the approximately 31,000 patients
operated on without unstable angina.
Similarly, of the 40,000 patients with unstable angina
undergoing PTCA, the in-hospital mortality was 1.5%,
which is threefold higher than the mortality in 48,000
patients undergoing PTCA without unstable angina. It thus
seems valid to state that clinically unstable angina triples the
procedural risk. At the same time, it is to be noted that the
OM in the extremely large New York State unstable angina
population was half that of the present study even though
56% of the patients were over 65 years of age and 27% of the
population had peripheral vascular disease. Thus, the inci-
dence of these two risk factors in the New York State
population was significantly higher than in the South
American patients enrolled in ERACI II.
The major strengths of the ERACI II study are its
extensive use of stents (315 deployed in 225 patients
assigned to PTCA) and its randomized design intended to
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offset patient selection bias and distribute measured and
unmeasured variables equally between the two study arms.
Randomization, however, does not guarantee a flawless
study, as is evidenced by the ascertainment bias that appears
to exist in this trial. The unequal length of time between
randomization to assigned treatment (9 days) and the
substantially longer hospital stay of the CABG arm (4.1
days) would be expected to increase detected events in the
CABG arm. The Q-wave MI would be the important
variable most likely to be influenced by these disparities
because MI was “judged to be present on the basis of a
review of all electrocardiograms obtained.” Similarly, be-
cause it is unlikely that all patients in both arms underwent
the protocol-specified dipyridamole thallium scintigraphy
within 30 days, it is reasonable to ask: How were the
missing data handled, and was the percentage of subjects
studied the same in each arm?
The follow-up data presented in the study are of very
little use for two reasons. First, as is obvious from an
inspection of Figures 3 and 4 (despite the expanded scale of
the abscissa for the first 3 months), the death and MI rates
are identical after 30 days, indicating that their excess during
the first 30 days was procedure related. Second, the coiled
stent chosen for this study was unfortunate because it has
subsequently been shown to have one of the highest
restenosis rates of all the stent devices. Additionally, it
seems most inappropriate to undertake a comparison of the
incidence of death and nonfatal MI during the 18-month
follow-up period in this study with the 36-month follow-up
period in EAST or the 12-month follow-up period in
GABI (4,5).
Germane to this study, which “hypothesized that stent
use might significantly decrease early complications in
comparison to coronary bypass surgery,” is a very recent
report by Hannan et al. (15) that compared both short- and
long-term outcomes between balloon angioplasty and cor-
onary stent placement from the New York State database.
This study found that risk-adjusted in-patient mortality
rates for PTCA and stent placement were not statistically
different; however, patients undergoing angioplasty were, on
average, significantly more likely to die at any point during
the two-year period after the index procedure than were
patients undergoing stent placement (relative risk 1.36, p 5
0.003). The risk-adjusted in-patient CABG rate for pa-
tients undergoing PTCA was also significantly higher
(2.72% vs. 1.66%, p , 0.001).
It would thus appear that the stage is set to undertake
studies that compare stent placement with CABG as a
function of both the number of vessels with disease and the
specific location of the disease within the vessel. The
ERACI II study further suggests to this reader that we
would be wise to compare stent placement with modern
medical treatment especially in the case of patients with
unstable angina. It is challenging to speculate what the
30-day outcome would have been had this stent-placement
study been compared to medical therapy that included
glycoprotein IIb/IIIa inhibitors, low molecular weight hep-
arin and clopidogrel for the 90% of the study population
who had unstable angina. This might just be the study that
has provided our first meaningful glimpse into the merits of
delaying coronary intervention for as much as 30 days in
patients with acute coronary syndromes.
Although I view their present study (11) as flawed, the
ERACI investigators made important contributions to our
search for improving coronary revascularization techniques,
especially by underscoring the need to examine both the
early and late outcomes of our therapeutic options. This will
become ever more important as we approach the 10-year
(plus) point of follow-up in many of the randomized trials.
Clearly, when long-term event curves cross, the indication is
that one of the procedures is preferable up to that point and
the other is preferable thereafter. Such considerations give
added meaning to the visionary words of the late Rene
Favaloro, who claimed from the very outset: “The two
techniques will always be complementary” (16).
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